Cerevel Therapeutics Holdings, Inc.
CEREDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CVL-562 (PF-06412562) 1 mg | Phase 2 | Early Course Schizophrenia Spectrum Disorder | - | - |
Frequently asked questions
What is in Cerevel Therapeutics Holdings, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Cerevel Therapeutics Holdings, Inc.'s (CERE) pipeline across Phase 2. Its lead program is CVL-562 (PF-06412562) 1 mg (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cerevel Therapeutics Holdings, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cerevel Therapeutics Holdings, Inc. (CERE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CERE biotech catalysts?→
Add CERE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cerevel Therapeutics Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.